Development of a novel strategy to cancel and prevent the drug resistance in myelodysplastic syndromes
Project/Area Number |
16K19186
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Applied pharmacology
|
Research Institution | Tokyo Medical University |
Principal Investigator |
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | アザシチジン / テリフルノミド / 薬剤耐性 / 骨髄異形成症候群 / ドラッグリポジショニング / がん / 薬理学 |
Outline of Final Research Achievements |
Previous studies showed that downregulation of pyrimidine salvage underlies resistance against 5-azacytidine (AZA), indicating an important role for de novo pyrimidine synthesis in AZA resistance. Because de novo pyrimidine synthesis is inhibited by the immunomodulator teriflunomide and its pro-drug leflunomide, we examined the effect of combined treatment with AZA and teriflunomide on AZA resistance to develop a novel strategy to cancel AZA resistance. Teriflunomide remarkably inhibited the growth of AZA-resistant human leukemia cell lines in comparison with their AZA-sensitive counterparts and activated pyrimidine salvage in AZA-resistant cells. In the presence of a non-toxic concentration of teriflunomide, AZA induced apoptosis in AZA-resistant cells and leukemia cells from AZA-resistant patients. These results suggest that combined treatment with AZA and teriflunomide can be a novel strategy to overcome AZA resistance.
|
Report
(3 results)
Research Products
(6 results)